Development Of a Concentrated Tranexamic Acid (TXA) Intramuscular Injection

Award NoticeAwarded

Información de Adjudicación

HEALTH AND HUMAN SERVICES, DEPARTMENT OF adjudicó este contrato a por $186,004,780 el September 30, 2025, como parte de federal procurement initiatives.

Esta adjudicación es parte de actividades de federal acquisition.

Número de Adjudicación
75A50125C00018
Monto de Adjudicación
$186,004,780
Fecha de Adjudicación
September 30, 2025

Puntos Clave

  • Competencia abierta completa - todas las empresas pueden participar
  • Trabajo a realizarse en WASHINGTON, DC
  • Industria: Research and Development in Biotechnology (except Nanobiotechnology)

Detalles del Contrato

ID de Aviso
75A50125C00018
Tipo de Oportunidad
Award Notice
Sub-Agencia
OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
Oficina
BARDA - ASPR / DAAPPO / BARDA DCMA
Fecha de Publicación
Wednesday, October 1, 2025
Fecha Límite de Respuesta
No especificado
Código PSC
AN13
Reserva
Competencia Abierta Completa
Lugar de Desempeño
WASHINGTON, DC, 20515
Estado
Activo

Descripción

This award is for the development of a concentrated Tranexamic Acid (TXA) Intramuscular Injection. The Government seeks this development in order to receive FDA approval for the concentrated IM TXA formulation that can be delivered in a pref-filled syringe or a dedicated autoinjector. This contract action was awarded competitively as a Cost Share Contract. A Cost Share Contract was used in accordance with FAR 35.006 (c) due to an absence of precise specifications and difficulties in estimating costs with accuracy.

Por Qué Importa Esta Oportunidad

HEALTH AND HUMAN SERVICES, DEPARTMENT OF está buscando respuestas para research and development in biotechnology (except nanobiotechnology) en WASHINGTON, DC.